Interviews

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes current educational needs around biosimilars.
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, describes the biosimilar approval pathway in the United States.
Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses experience with biosimilar pegfilgrastim so far.
Lee Schwartzberg, MD, FACP, medical director and senior partner at The West Clinic, discusses his research that showed that the incidence of febrile neutropenia was similar between patients who received reference filgrastim versus those who received a biosimilar. 
Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the European experience with using nonproprietary names for biosimilar pharmacovigilance. 
Anton Franken, MD, PhD, endocrinologist, discusses how to communicate with patients who are going to be switched to biosimilar insulin.
Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), explains how a recent trade deal could take a toll on biosimilars.
James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses how the FDA plans to address citizen petitions that impede market entry of competitive products. 
Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the FDA’s recent guidance on the naming of biosimilars, biologics, and interchangeable products. 
Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, describes imporant considerations in preparing for the arrival of biosimilar rituximab. 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.